This Day On The Street
Continue to site
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

The Leukemia & Lymphoma Society Launches Expanded Man & Woman Of The Year Campaign





Two, 10-week fundraising campaigns supporting LLS's vision of a world without blood cancer will kick off in April

SAN FRANCISCO, March 21, 2013 /PRNewswire-USNewswire/ -- The Greater Bay Area chapter of The Leukemia & Lymphoma Society (LLS) will launch its 23 rd annual San Francisco Man & Woman of the Year fundraising campaign on April 4, 2013 at the University Club in San Francisco and its inaugural North Bay Man & Woman of the Year campaign on April 18, 2013 at a private home in Sonoma.

Thirteen Bay Area candidates will dedicate ten weeks to cultivating donations for vital blood cancer research and services for patients and their families. The San Francisco and North Bay campaigns will run almost concurrently and offer an array of opportunities for the community to support LLS's vision of a world without blood cancer. The candidates who raise the most money will be named the San Francisco or North Bay Man & Woman of the Year. Below please find a list of this year's candidates, several of whom have been touched by blood cancer.

2013 CANDIDATES FOR SAN FRANCISCO MAN & WOMAN OF THE YEAR

David Bevilacqua (He is a lymphoma survivor) Dominic Chan Steve ChenEric Dew  Jackie Omotalade Christopher Orr Tanya Petrossian Christina Resasco Marc Rosenberg Tatiana Takaeva Paul Tuan Jennifer Zanotto

2013 CANDIDATES FOR INAUGURAL NORTH BAY MAN & WOMAN OF THE YEAR

Joanne Sanders Fran Templin Katie Leonardini

LLS IS ACCELERATING NEW CANCER THERAPIES AND SAVING LIVES

Since 1949, LLS has invested more than $875 million to develop better cancer treatments. Since the early 1960s, the survival rate for many with leukemia, lymphoma, myeloma and related blood malignancies has doubled, tripled and even quadrupled. Nearly half of all cancer drugs first approved by the Food and Drug Administration (FDA) since 2000 were developed for blood cancer patients. Thanks to LLS support, thousands of Bay Area blood cancer patients today live normal lives. Some manager their condition with just a daily pill, rather than suffer acute treatment such as chemotherapy or radiation as in years past.

CAMPAIGN HONORS TWO YOUNG SURVIVORS

This year's San Francisco campaign honors two young and courageous survivors of acute lymphoid leukemia (ALL) – Sarah, age 11, of Pleasanton and Rhett, age 5, of Corte Madera. After two and a half years of treatment, Sarah is a typical 5 th-grader. She enjoys swimming playing softball, cheering on her favorite baseball team (the Giants) and playing with her friends. Rhett is on the tail-end of treatment and his prognosis is good. His cancer cell counts are few and his chemotherapy is less intense. Today, he is back at school and enjoys running and playing just like other preschoolers his age.

Our inaugural North Bay campaign also honors two children with ALL – Hanna, age 5, of Santa Rosa and Brody, age 3 of Rohnert Park. Both are still undergoing treatment, although Hanna's official end of treatment is scheduled for March 29, 2013. Hanna loves to play dress up, play with dolls and dance. Brody, on the other hand, is about a year into treatment; he was diagnosed in January 2012. Brody loves to ride his bike and play with trucks and his older brother.

In 1960, a child with leukemia had a four percent chance of survival.  Advancements in treatment have led to an eighty-five percent survival rate today.  However, despite the increased survival rates, the number of leukemia patients has almost doubled and the number of lymphoma patients has tripled since 1975.

1 of 2

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
SYM TRADE IT LAST %CHG

Markets

DOW 18,080.14 +21.45 0.12%
S&P 500 2,117.69 +4.76 0.23%
NASDAQ 5,092.0850 +36.0220 0.71%

Partners Compare Online Brokers

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs